Why Personalized Medicine Poses HTA & Funding Challenges In England

Personalized medicine models could benefit patients, but this approach raises tough economic and prioritization questions for health technology assessment bodies like England’s NICE.

Japan's HTA Scheme Entered Fourth Year With 14 Drugs Under Its Evaluation.
• Source: Shutterstock

England’s health technology assessment (HTA) body, NICE, must allocate resources towards medicines that “have the greatest impact on the whole population,” something that makes it “tricky” to implement personalized medicine within the National Health Service, according to Clare Morgan, director of implementation and partnerships at NICE.

“People accessing the health and care system need and want access to the best care, and the personalization route is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from AI

More from Advanced Technologies